THE CANCER TERMINATOR
PNC-27
Selective cancer cell destruction that spares healthy cells
Also known as: HDM-2 Binding Peptide
Overview
PNC-27 is a synthetic peptide designed to selectively kill cancer cells while leaving healthy cells unharmed. It works by binding to HDM-2, a protein that cancer cells overexpress on their surface, and then forming pores in their membranes. This liberates the p53 tumor suppressor, allowing it to trigger cancer cell death. It's being researched for various cancers.
Key Benefits & Mechanisms
HDM-2 Binding
Binds to HDM-2 protein overexpressed on cancer cells
p53 Liberation
Frees p53 tumor suppressor to activate apoptosis
Membrane Pores
Forms channels in cancer cell membranes causing necrosis
Selectivity
Spares healthy cells lacking HDM-2 overexpression
Dosing Guide
Dosage
250 mcg daily (research protocol)
Schedule
daily
Cycle
6 weeks on, 8 weeks off
Pro Tip
Only for research use - not approved for human treatment
Safety Profile
Caution Advised
Use Caution
Not approved for clinical use. Safety profile not established in humans.
Experimental research compound only. Source quality is a major concern.
Possible Side Effects
What to Expect
Week 1-2
Peptide begins targeting cancer cells (in vitro)
Week 2-4
Cell death in susceptible cancer types (research)
Week 4-6
Potential tumor reduction (animal models only)
Effects on cancer cells seen in lab studies; human data limited.
Who Is This For
Research References
Ready to Start Your Peptide Journey?
Track your protocols, get guided reconstitution, and access our vetted vendor network — all in one app.
Download The Peptide App